Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | MMP13 | P45452 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700908 | 0.92 | MMP13 (0.55) | KDM4ECYP3A4CYP2C9MMP13MAPT | |
| SCHEMBL6701195 | 0.82 | MMP13 (0.58) | KDM4ECYP3A4CYP2C9MMP13MAPT | |
| SCHEMBL6703820 | 0.82 | MAPK1 (0.56) | KDM4ECYP3A4CYP2C9MAPTLMNA | |
| SCHEMBL2118644 | 0.82 | HDAC6 (0.46) | CYP2C9HPGDHTTSMN1; SMN2 | |
| SCHEMBL6697167 | 0.80 | MMP13 (0.58) | KDM4ECYP3A4CYP2C9MMP13MAPT | |
| SCHEMBL2116432 | 0.80 | HDAC6 (0.56) | MMP13NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6702695 | 0.79 | MEN1 (0.48) | CYP2C9POLBHPGDHTTSMN1; SMN2 | |
| SCHEMBL4550180 | 0.79 | SMPD1 (0.56) | — | |
| SCHEMBL2619344 | 0.79 | SMPD1 (0.50) | CYP2C9HPGDHTTSMN1; SMN2 | |
| SCHEMBL10268001 | 0.78 | HDAC6 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | MMP1, MMP13, MMP9 | KDM4E 1326/4885CYP3A4 598/4885CYP2C9 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.